Shinsei Capital Partners
Venture capitalTokyo · Pre-Seed–Late Stage
Also known as 新生キャピタルパートナーズ株式会社
Investment thesis
The firm sees Japan's life sciences sector as globally competitive thanks to sustained research by universities, institutions, and pharmaceutical companies. Its mission is to financially support these research outcomes to bring innovative medicines to patients and drive practical commercialization. Managing the New Life Science No.1 fund, it invests in drug-discovery ventures across company creation, seed, early, middle, and later stages, drawing on decades of combined expertise in finance and drug development to enable technology-driven innovation in healthcare.
Source: firm website, verified Aug 3, 2026.
What they invest in
from 6 of 7 portfolio companiesBiotech ×6Deep Tech ×4Healthtech ×4Medical Devices ×3AI & Machine Learning ×1Digital Health ×1
HQs:Japan×6
Investments · 7 tracked
founders shown can be your intro pathAlphaNavi Pharma is a pharmaceutical company developing new drugs (Nav channel inhibitors) for patients suffering from chronic pain and neurological disorders.
BiotechDigital HealthHealthtech京都市, JP
小山田義博Yoshihiro Oyamada(Representative Director)
Co-investorsKyoto University Innovation Capital
Cancer therapeutics development (RNA regulation abnormalities).
Co-investorsKyoto University Innovation CapitalNippon Venture CapitalSMBC Venture CapitalUTokyo Innovation Platform Co. Ltd.
FREST is a Japanese biotech venture developing RNA editing technology (RNA editing nucleic acids) that edits gene structure at the mRNA level to create nucleic acid drugs for genetic and currently untreatable diseases.
BiotechDeep TechMedical DevicesFujisawa, JP
福田 将虎(Founder & Scientific Advisor)高橋 信明(代表取締役社長・CEO (President & CEO))
MiraBiologics is a Japanese biopharmaceutical drug discovery company that uses its LassoGraft Technology to graft cyclic peptides onto scaffold proteins for the development of novel biologics.
BiotechDeep TechHealthtechTokyo, JP
Hiroaki Suga(Co-founder; Professor, University of Tokyo)Junichi Takagi(Co-founder; Director & Professor, Osaka University)Masuhiro Kato(Representative Director & President)Igarashi(Chief Operating Officer)
Veritas In Silico develops AI-driven drug discovery platforms targeting RNA and nucleic acid-based therapeutics, partnering with pharmaceutical companies for small molecule and mRNA drug creation.
AI & Machine LearningBiotechDeep TechMedical DevicesKawasaki, JP
Shingo Nakamura(CEO)
Co-investorsGlobal BrainKDDI Open Innovation FundNippon Venture CapitalSMBC Venture Capital
TWOCELLS (株式会社ツーセル) is a regenerative medicine venture developing therapies and products based on mesenchymal stem cells (MSCs), including its gMSC series for cartilage regeneration, along with serum-free culture media (STK series) and consulting services.
BiotechHealthtechMedical DevicesHiroshima, JP
松本 昌也(代表取締役社長)
Co-investorsHiroshima Venture Capital Co. Ltd.
Modalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development.
BiotechDeep TechHealthtechTokyo, JP
Haruhiko Morita(代表取締役CEO (President & CEO))
Co-investorsMedical Incubator Japan K.K.Nippon Venture CapitalSMBC Venture CapitalUTokyo Innovation Platform Co. Ltd.
Portfolio news
latest coverage across their companies
Chordia Therapeutics · markets.businessinsider.com · Aug 14, 2026
Veritas In Silico · finance.yahoo.com · Apr 21, 2026
Frequently asked questions
- How many investments has Shinsei Capital Partners made?
- Shinsei Capital Partners has 7 tracked investments.
- What stage does Shinsei Capital Partners invest at?
- Shinsei Capital Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Shinsei Capital Partners focus on?
- Shinsei Capital Partners focuses on Biotech, Digital Health, Sector Agnostic.
- Where is Shinsei Capital Partners located?
- Shinsei Capital Partners is headquartered in Tokyo, JP.
- Who does Shinsei Capital Partners co-invest with?
- Shinsei Capital Partners most often shares deals with Nippon Venture Capital, SMBC Venture Capital, Kyoto University Innovation Capital, among 8 tracked co-investors.
Images
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
.png)
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Speedinvest operates a Portfolio Success program that connects its 400+ portfolio startups with customers, follow-on investors, industry experts, talent, discounted tools, and fellow founders across Europe, the Middle East, Africa, and beyond.